✅ Product Benefits
-
Broad-spectrum antifungal activity: Voriconazole inhibits ergosterol synthesis in fungal cell membranes, effectively treating a variety of serious fungal infections, including invasive aspergillosis, candidemia, and infections caused by Fusarium and Scedosporium species.
-
Suitable for both adults and children: Approved for use in adults and children aged 2 years and older, making it a versatile option for treating serious fungal infections across different age groups.
-
Convenient oral administration: Available in tablet form, Voricare 200 mg is taken orally, offering a convenient treatment option for patients.
-
Manufactured by Delta Pharma Ltd.: Produced by a reputable pharmaceutical company in Bangladesh, ensuring quality and compliance with local regulatory standards.
ℹ️ Precautions & Safety Notes
-
Liver and kidney function: Use with caution in patients with liver or kidney impairment. Dose adjustments may be necessary based on individual health status.
-
Drug interactions: Voriconazole may interact with medications metabolized by the cytochrome P450 system, such as phenytoin, efavirenz, and sirolimus. Monitoring and dose adjustments may be required when co-administered with these drugs.
-
Pregnancy and breastfeeding: Classified as Category D for pregnancy; should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is not known whether voriconazole is excreted in human breast milk; therefore, caution should be exercised when administered to a nursing mother.
-
Photosensitivity: Voriconazole may increase sensitivity to sunlight. Patients should avoid direct sunlight exposure and use protective clothing and sunscreen when outdoors.
-
Contraindications: Contraindicated in patients with known hypersensitivity to voriconazole or any component of the formulation.
Offer Products
Face Care
Hair Care
stationery & office
Tea & Coffee
Baby Wipes
Cream
Baby Essentials
Fragrances
Lip Care
Body Care
Air Freshener
Customer questions & answers
Customer reviews
0 out of 5